Investor directory

NantKwest

NantKwest is a clinical-stage immunotherapy company focused on harnessing the immune system to treat disease. It is a biotechnology company, engages in developing immunotherapeutic agents for various clinical conditions in the United States. The company’s product candidates include activated natural killer candidates for the treatment of virally-induced cancers, such as human papilloma virus-induced cervical, and head and neck cancers; ebola; and serious viral, fungal, and bacterial infections, as well as that is in Phase II clinical trials for the treatment of polyoma virus-induced merkel cell carcinoma.
http://nantkwest.com
https://crunchbase.com/organization/nantkwest
https://facebook.com/immunitybio1
https://linkedin.com/company/nantkwest
https://pitchbook.com/profiles/company/54113-41
https://twitter.com/nantkwest
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=262241549

Patrick Soon-Shiong

Executive Chairman and CEO

1 past transactions

Viracta Therapeutics

Series B in 2017
Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, focused on precision oncology for virus-associated malignancies. The company specializes in a viral activation therapy platform aimed at treating cancers linked to the Epstein-Barr Virus (EBV) and other virus-associated diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir in Phase 2 clinical trials for EBV-positive lymphoma, including conditions such as post-transplant lymphoproliferative disorder and plasmablastic lymphoma. Viracta is also exploring the application of this therapeutic approach in treating other EBV-related malignancies, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and previously known as HemaQuest Pharmaceuticals, Viracta Therapeutics continues to advance its mission to develop innovative treatments for serious viral-associated cancers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.